Cilostazol is useful for the treatment of sinus bradycardia and associated hemodynamic deterioration following heart transplantation

Tomoki Uchikawa, Takeo Fujino, Taiki Higo, Kisho Ohtani, Akira Shiose, Hiroyuki Tsutsui

研究成果: ジャーナルへの寄稿記事

抄録

Bradycardia is a common complication at the early postoperative period after heart transplantation (HT). The heart rate (HR) usually recovers within a few weeks; however, several patients need a temporary pacemaker or chronotropic agents to stabilize their hemodynamics. Here, we report the first case of transient bradycardia associated with hemodynamic deterioration following HT, which was successfully treated with cilostazol, a phosphodiesterase-3-inhibiting agent. A 59-year-old man received HT for advanced heart failure due to ischemic cardiomyopathy. General fatigue persisted even after the HT. His HR was around 60 beats per minute (bpm) with sinus rhythm. Echocardiography showed no abnormal findings. Right heart catheterization showed that the cardiac index (CI) was 1.9 L/minute/m2. Continuous intravenous infusion of isoproterenol (0.003 μg/kg/minute) increased the HR to 80 bpm and CI to 2.7 L/minute/m2 and improved his symptoms. Isoproterenol was switched to oral administration of cilostazol (100 mg, twice a day), which maintained the HR at around 80 bpm and CI of 2.5 L/minute/m2. The patient’s HR gradually recovered and cilostazol could be discontinued three months after the HT. Oral administration of cilostazol can be a therapeutic option for patients with sinus bradycardia following HT, who need positive chronotropic support.

元の言語英語
ページ(範囲)1222-1225
ページ数4
ジャーナルInternational heart journal
60
発行部数5
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Heart Transplantation
Bradycardia
Hemodynamics
Heart Rate
Isoproterenol
Oral Administration
Therapeutics
Phosphoric Diester Hydrolases
Cardiac Catheterization
Cardiomyopathies
Postoperative Period
Intravenous Infusions
Fatigue
Echocardiography
cilostazol
Heart Failure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Cilostazol is useful for the treatment of sinus bradycardia and associated hemodynamic deterioration following heart transplantation. / Uchikawa, Tomoki; Fujino, Takeo; Higo, Taiki; Ohtani, Kisho; Shiose, Akira; Tsutsui, Hiroyuki.

:: International heart journal, 巻 60, 番号 5, 01.01.2019, p. 1222-1225.

研究成果: ジャーナルへの寄稿記事

@article{f57bd747ba78442e8e50592660875554,
title = "Cilostazol is useful for the treatment of sinus bradycardia and associated hemodynamic deterioration following heart transplantation",
abstract = "Bradycardia is a common complication at the early postoperative period after heart transplantation (HT). The heart rate (HR) usually recovers within a few weeks; however, several patients need a temporary pacemaker or chronotropic agents to stabilize their hemodynamics. Here, we report the first case of transient bradycardia associated with hemodynamic deterioration following HT, which was successfully treated with cilostazol, a phosphodiesterase-3-inhibiting agent. A 59-year-old man received HT for advanced heart failure due to ischemic cardiomyopathy. General fatigue persisted even after the HT. His HR was around 60 beats per minute (bpm) with sinus rhythm. Echocardiography showed no abnormal findings. Right heart catheterization showed that the cardiac index (CI) was 1.9 L/minute/m2. Continuous intravenous infusion of isoproterenol (0.003 μg/kg/minute) increased the HR to 80 bpm and CI to 2.7 L/minute/m2 and improved his symptoms. Isoproterenol was switched to oral administration of cilostazol (100 mg, twice a day), which maintained the HR at around 80 bpm and CI of 2.5 L/minute/m2. The patient’s HR gradually recovered and cilostazol could be discontinued three months after the HT. Oral administration of cilostazol can be a therapeutic option for patients with sinus bradycardia following HT, who need positive chronotropic support.",
author = "Tomoki Uchikawa and Takeo Fujino and Taiki Higo and Kisho Ohtani and Akira Shiose and Hiroyuki Tsutsui",
year = "2019",
month = "1",
day = "1",
doi = "10.1536/ihj.19-116",
language = "English",
volume = "60",
pages = "1222--1225",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "5",

}

TY - JOUR

T1 - Cilostazol is useful for the treatment of sinus bradycardia and associated hemodynamic deterioration following heart transplantation

AU - Uchikawa, Tomoki

AU - Fujino, Takeo

AU - Higo, Taiki

AU - Ohtani, Kisho

AU - Shiose, Akira

AU - Tsutsui, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bradycardia is a common complication at the early postoperative period after heart transplantation (HT). The heart rate (HR) usually recovers within a few weeks; however, several patients need a temporary pacemaker or chronotropic agents to stabilize their hemodynamics. Here, we report the first case of transient bradycardia associated with hemodynamic deterioration following HT, which was successfully treated with cilostazol, a phosphodiesterase-3-inhibiting agent. A 59-year-old man received HT for advanced heart failure due to ischemic cardiomyopathy. General fatigue persisted even after the HT. His HR was around 60 beats per minute (bpm) with sinus rhythm. Echocardiography showed no abnormal findings. Right heart catheterization showed that the cardiac index (CI) was 1.9 L/minute/m2. Continuous intravenous infusion of isoproterenol (0.003 μg/kg/minute) increased the HR to 80 bpm and CI to 2.7 L/minute/m2 and improved his symptoms. Isoproterenol was switched to oral administration of cilostazol (100 mg, twice a day), which maintained the HR at around 80 bpm and CI of 2.5 L/minute/m2. The patient’s HR gradually recovered and cilostazol could be discontinued three months after the HT. Oral administration of cilostazol can be a therapeutic option for patients with sinus bradycardia following HT, who need positive chronotropic support.

AB - Bradycardia is a common complication at the early postoperative period after heart transplantation (HT). The heart rate (HR) usually recovers within a few weeks; however, several patients need a temporary pacemaker or chronotropic agents to stabilize their hemodynamics. Here, we report the first case of transient bradycardia associated with hemodynamic deterioration following HT, which was successfully treated with cilostazol, a phosphodiesterase-3-inhibiting agent. A 59-year-old man received HT for advanced heart failure due to ischemic cardiomyopathy. General fatigue persisted even after the HT. His HR was around 60 beats per minute (bpm) with sinus rhythm. Echocardiography showed no abnormal findings. Right heart catheterization showed that the cardiac index (CI) was 1.9 L/minute/m2. Continuous intravenous infusion of isoproterenol (0.003 μg/kg/minute) increased the HR to 80 bpm and CI to 2.7 L/minute/m2 and improved his symptoms. Isoproterenol was switched to oral administration of cilostazol (100 mg, twice a day), which maintained the HR at around 80 bpm and CI of 2.5 L/minute/m2. The patient’s HR gradually recovered and cilostazol could be discontinued three months after the HT. Oral administration of cilostazol can be a therapeutic option for patients with sinus bradycardia following HT, who need positive chronotropic support.

UR - http://www.scopus.com/inward/record.url?scp=85072747062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072747062&partnerID=8YFLogxK

U2 - 10.1536/ihj.19-116

DO - 10.1536/ihj.19-116

M3 - Article

C2 - 31484879

AN - SCOPUS:85072747062

VL - 60

SP - 1222

EP - 1225

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 5

ER -